Tarenflurbil
As of the edition of 20 October 2026, Tarenflurbil is a small molecule: went quiet in 2014; acts on PSEN1 and PSEN2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2014
- Kind
- Small molecule
- Registered trials
- 5, 2 stopped early
- Disease areas
- Mental health; Nervous system; Cancer; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 3 | 3 | 1 | 0 | 2 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Myrexis | Lead sponsor of trials | 2002 to now |